What it is
Epithalon (also spelled Epitalon, and sometimes Epithalone/Epitalone) is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, written Ala-Glu-Asp-Gly or AEDG. It was designed and first studied by the Russian researcher Vladimir Khavinson, of the St. Petersburg Institute of Bioregulation and Gerontology, to reproduce the biological activity of an older preparation called Epithalamin (also Epithalamine) — a mixed polypeptide extract originally isolated from bovine pineal gland tissue. Epithalamin is a complex extract; Epithalon/Epitalon is the single defined tetrapeptide built to imitate part of its activity, and a later Khavinson-group paper reported detecting the AEDG sequence within the pineal polypeptide complex itself by mass spectrometry. The two names are frequently used interchangeably online and in parts of the older Russian literature, but they are not the same material, and that distinction matters for reading the evidence below: the human studies most often cited for this compound tested Epithalamin, the extract, not the synthetic tetrapeptide sold today as Epithalon or Epitalon.
The compound has no approved medical use anywhere reviewed for this entry, is not the active ingredient of any marketed drug, and has no entry on ClinicalTrials.gov under any spelling searched, including Epitalon, Epithalon, Epithalone, and the chemical name “AEDG peptide.” It is sold by research-chemical vendors under a “research use only” framing and circulates in online longevity and anti-aging communities on the strength of a handful of small studies and a widely repeated claim about telomerase activation, discussed in the mechanism section below.
Mechanism, and a caution about where the evidence for it comes from
Melatonin and circadian rhythm
The most consistently reported effect, across both animal and small human studies, involves the pineal gland’s own hormone, melatonin. In old rhesus monkeys, Epitalon was reported to raise basal night-time melatonin and improve glucose-tolerance-test dynamics, with no effect seen in young monkeys — an animal study. In small groups of elderly human subjects, researchers reported that a course of Epithalamin tended to raise night-time plasma melatonin in people whose baseline pineal output was already low, while tending to lower it slightly in those with normal baseline function, which the authors described as a “normalizing” rather than simply stimulant effect. A 2024 narrative review from the same research group extended this to a proposed cellular mechanism, stating that the peptide affects circadian-clock gene expression (citing genes such as Cry2, AANAT, ASMT and CLOCK) measured in buccal epithelium cells, and reduces expression of certain apoptosis-related proteins — but that review summarizes the same institute’s own prior work rather than reporting new independently generated data.
The telomerase claim: what it is actually based on
Epithalon’s reputation rests heavily on a claim that it activates telomerase, the enzyme that rebuilds the protective caps (telomeres) on the ends of chromosomes, and by extension on the idea that it might slow cellular aging. That claim needs to be stated carefully, because of what actually supports it. The original findings came from Khavinson’s own laboratory: in 2003, the group reported that adding Epithalon to telomerase-negative human fetal fibroblast cell cultures induced expression of the enzyme’s catalytic subunit, telomerase activity, and telomere elongation. A 2004 follow-up from the same lab, in the same journal, reported that peptide-treated aging fibroblasts underwent roughly ten additional cell divisions before reaching replicative senescence compared with untreated cells, which the authors described as overcoming the Hayflick limit. Both of these are in vitro, cell-culture findings from a single research group, and no independent verification of either was described at the time.
The first genuinely independent check on this claim came only in 2025, from a UK academic group at Brunel University London’s Centre for Genome Engineering and Maintenance, unconnected to Khavinson’s network. Treating breast cancer cell lines and normal epithelial and fibroblast cells with Epitalon, they reported dose-dependent telomere lengthening in normal cells through telomerase (hTERT) upregulation, and telomere extension in the cancer cell lines through a different pathway, called Alternative Lengthening of Telomeres, that does not rely on telomerase. This study, published in Biogerontology (with a subsequent correction), is the one clearly independent piece of evidence located for this entry that supports part of the mechanistic story, and it deserves to be stated plainly as such. It is still cell-culture work, not a human or even a whole-animal finding, and it also identified a mechanistic complication — activation of a cancer-associated telomere-lengthening pathway in the cancer lines — that was not part of the original claim. No study located for this entry has measured telomerase activity or telomere length in blood or tissue taken from a living human being who received Epithalon or Epitalon. The signature claim behind this compound’s reputation has never been shown to occur inside a treated person.
Other proposed mechanisms
Secondary claims in the literature include effects on gene expression tied to interleukin-2 and thymocyte activity, effects on enzymes including acetylcholinesterase and telomerase, and effects on retinal cell proliferation in culture and in a rat model of hereditary retinal degeneration. Each of these traces back to the same research network, and in at least two cases — a claimed effect on the CDC2 cell-cycle gene, and the specific interleukin-2/thymocyte study referenced in review articles — a direct search for the primary paper returned no result, meaning the underlying study could not be located or checked for design or sample size for this entry.
What the human evidence actually shows
A single research network, not independent replication
Every human study located for this entry that reports an efficacy or clinical outcome for Epithalon, Epitalon, or Epithalamin comes from Vladimir Khavinson himself, from his long-term collaborators Oleg Korkushko and Valentina Shatilo at the Institute of Gerontology in Kiev, or from other closely affiliated co-authors at the same St. Petersburg institute. No independently authored human clinical trial of any of these names was found. Several of the human studies used Epithalamin, the polypeptide pineal extract given as periodic treatment “courses,” rather than a stated milligram dose of the synthetic AEDG tetrapeptide — an important distinction the rest of this section preserves.
A 2006 report described a study following elderly patients with coronary disease and signs of accelerated cardiovascular aging over twelve years, comparing those given Epithalamin against a control group, and reported 28 percent lower overall mortality and roughly half the cardiovascular mortality and cardiovascular/respiratory illness incidence in the treated group. A 2011 report from the same group followed 39 coronary patients given Epithalamin alongside standard therapy against 40 controls over three years, with fifteen-year mortality follow-up, and reported decelerated cardiovascular aging markers and significantly lower mortality in the treated group. A 2004 report from the same authors measured circadian plasma melatonin in healthy elderly subjects before and after a course of Epithalamin and reported the normalizing pattern described above. A 2003 report by Khavinson and a co-author followed 266 elderly and older adults for six to eight years, comparing groups given a thymus-derived peptide (Thymalin), Epithalamin, both, or neither, and reported reductions of roughly half to two-thirds in acute respiratory illness and reductions in mortality ranging from 1.6-fold to as much as 4.1-fold in a subgroup given both peptides annually for six years.
These numbers sound substantial, and the entry states them because they are what the papers report — but every one of these studies is small to moderate in size (39 versus 40 patients in one case; 266 total split across several arms in the largest), every one is described in its own abstract without a stated blinding method or placebo arm for most of them, none was located with a publicly accessible protocol, and none is registered on ClinicalTrials.gov or any comparable registry. One study in this set, examining Epithalamin in women with heart disease and hypertension, does carry a double-blind designation in its indexed record, but its detailed methodology was not retrieved for this entry. Read only from what could be gathered here, a neutral reviewer would have to describe this body of work as a single research network’s multi-decade, mostly open-label program, reported in Russian regional gerontology journals and one editorially unusual international journal, that has not been reproduced by any outside group. No study in this set gives a human dose, injection route, or treatment duration for the synthetic Epitalon tetrapeptide itself — only for Epithalamin, the different, older preparation.
Safety
Structured human safety data for this compound are essentially absent. A direct search for toxicity or adverse-event reporting on Epitalon returned no results. What exists instead is scattered through the efficacy papers described above: one review from the treating research group itself states that the pineal peptide preparations raise melatonin “with no side effects,” which is an assertion by the group running the studies, not a systematically collected adverse-event dataset, and should not be read as an established safety finding. No study located for this entry reports a structured adverse-event table, a count of dropouts due to toxicity, routine laboratory safety monitoring such as liver or kidney function tracking, or a maximum tolerated human dose. No immunogenicity data — whether the body forms antibodies against the peptide, a documented concern for other synthetic peptides in this project’s other entries — were found for Epithalon in humans. No long-term human safety follow-up beyond the mortality and illness counts reported by the treating group itself, discussed above, was located. Formal animal toxicology, of the repeat-dose, genotoxicity or reproductive-toxicity kind typically run before human dosing, was likewise not located; the animal papers that exist measure physiological endpoints like melatonin and glucose, not a toxicology program.
Cancer risk in either direction is unresolved. Rodent breast-cancer models have reported that Epithalamin and Epitalon inhibit mammary tumor development, and a separate line of more recent, unrelated research used Epitalon’s telomere-related activity as a tool to selectively target chemoresistant senescent cancer cells in mouse models — a specific laboratory application, not evidence of a general anti-cancer or pro-cancer effect in ordinary human use. No human cancer-outcome data of any kind exist for this compound. In short: this is a compound with almost no structured human safety record, marketed into a wellness and longevity audience that is unlikely to be monitored the way a clinical trial participant would be.
Regulatory status
Epithalon and Epitalon have no FDA approval and no EMA approval, and neither is the subject of any identified New Drug Application, Biologics License Application, or Marketing Authorisation Application in the US or EU. No FDA warning letter naming Epitalon or Epithalon specifically was located for this entry, though a 2026 pharmacy-compounding trade journal article discussed “Epitalon” by name alongside several other unapproved research peptides — including BPC-157, KPV, MOTS-c, Semax and TB-500 — as part of a wider review of compounded research peptides, describing these compounds generally as promoted for a wide range of uses and examining the concerns raised during that review. What a specific Russian regulatory registration, category, or current status might be for Epitalon, Epithalon, or the older Epithalamin preparation could not be confirmed from the sources available for this entry, and no claim about Russian approval or supplement status should be read into this entry beyond that. Its status under the World Anti-Doping Agency’s Prohibited List was also not directly checked as part of this research and should not be assumed one way or the other.
Separately from any research literature, independent Belgian public-health forensic chemists identified the Epitalon tetrapeptide, using mass spectrometry, in two illegally sold pharmaceutical preparations marketed for cancer, old age, and retinitis pigmentosa. That finding, from analysts with no connection to Khavinson’s research network, confirms that the compound does circulate in unregulated and in at least one documented case illegal preparations, and that the material found matched what it was claimed to be — but it says nothing about whether that material is safe or effective for any use.
What the record gets wrong
Epithalon is, among the compounds covered on this site, one of the clearest cases where a compound’s online reputation has outrun its evidence base, and the gap is specific rather than vague. The “telomerase activation” and “reverses cellular aging” language attached to this peptide across wellness and longevity content typically cites the Khavinson group’s in vitro fibroblast work and the rodent lifespan studies without disclosing three things this entry has tried to state plainly: that the human “geroprotector” trials come entirely from one interlinked research network and were never independently replicated; that the telomerase claim itself has only ever been demonstrated in cultured cells, never in a living human being; and that the human clinical literature is largely about a different, older preparation — Epithalamin, the polypeptide extract — rather than about the synthetic AEDG tetrapeptide sold today under the Epithalon and Epitalon names. A single 2025 independent in vitro replication of part of the telomerase mechanism, from a UK academic group with no tie to Khavinson’s institute, is real and worth noting, but it changes none of this: it is still cell-culture work, and it does nothing to validate the human mortality and morbidity figures reported by the original research group. Until an outside laboratory or clinical group independently reproduces the human findings, and until someone establishes a human dose, route, and pharmacokinetic profile for the synthetic tetrapeptide itself rather than for the older pineal extract, this compound’s human evidence base should be read as a single research program’s decades-long report on its own work, not as an independently confirmed finding.